N2Growth Blog

OCTOBER 26, 2023

Moreover, governance excellence is synonymous with nurturing a culture of transparency, trust, and ethical behavior. Moreover, the board’s critical role extends to risk management, ensuring robust processes are in place to identify, assess, and mitigate risks, bolstering the organization’s success trajectory.

Succession 396

Succession Ethics Diversity Objective 396

Harvard Business Review

JUNE 9, 2017

Legitimate concerns over conflict of interest that have resulted in overly extreme preventative policies are a central cause. It is time for all parties to revisit those policies and replace them with rules that recognize both true conflicts and true confluences of interest. Insight Center. Sponsored by Optum. Research.

Conflict of Interest 10

Conflict of Interest Pharmaceuticals Policies Industry 10

Harvard Business Review

JUNE 2, 2014

But as Steve Blank, Henry Chesbrough, and others have pointed out , that advantage is offset by the daunting fact that corporate innovators have to fight a war on two fronts. This is where the concept of stealth innovation can help you. To some extent, you can secure the necessary flexibility by negotiating it up front.

Innovation 12

Innovation Conflict of Interest Strategy System 12

Harvard Business Review

SEPTEMBER 12, 2012

Equating "innovative" with new molecules misses the point: to develop clinically superior new medicines. The apparent business model of Big Pharma emphasizes the billions spent at great risk to find "innovative" and "breakthrough" new molecules that must be priced high to recover research costs that have become "unsustainable."

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. For instance, 60 institutional investors, collectively managing more than $5.5

Reputation 8

Reputation Pharmaceuticals Price Business Model 8